Research Reflections: Barzi Reviews CRC Updates From ASCO GI 2022

Welcome to OncLive On Air^®! I’m your host today, Caroline Seymour.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Afsaneh Barzi, MD, PhD, an associate professor in the department of Medical Oncology and Therapeutics Research at City of Hope, to discuss interesting findings from the 2022 ASCO Gastrointestinal Cancers Symposium, focusing on studies of clinical importance for patients with colorectal cancer (CRC).

Dr Barzi explained that the field of CRC does not produce new agents as frequently as other cancers, but oncologists do a good job of optimizing existing agents, so it is important to stay abreast of the latest developments.

During our exclusive interview, Dr Barzi discussed data from the ACCENT and RESPECT trials evaluating the value of oxaliplatin for patients with CRC, results from an investigation of nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with high tumor mutational burden, and more.

Check back on Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive^® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.